A study of DEL106.
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2017
At a glance
- Drugs DEL 106 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- 30 Jan 2017 New trial record
- 26 Jan 2017 According to a Celgene Corporation media release, company is planning to initiate this trial in 2018.